Related Experiment Videos
CB694, a novel antimitotic with antitumor activities
Kimberly N Weiderhold1, Deborah A Randall-Hlubek, Lisa A Polin
1Department of Physiology and Medicine, Southwest Foundation for Biomedical Research, San Antonio, TX 78425-0549, USA.
International Journal of Cancer
|September 10, 2005
Summary
A novel compound, CB694, effectively inhibits cancer cell proliferation by disrupting microtubule assembly and causing mitotic arrest. This antimitotic agent shows promise against multidrug-resistant cells and demonstrates antitumor activity in vivo.
Area of Science:
- Pharmacology
- Cell Biology
- Medicinal Chemistry
Background:
- Antimitotic agents are crucial in cancer therapy.
- Novel compounds are needed to overcome drug resistance.
- Microtubule-targeting drugs are a key class of antimitotics.
Purpose of the Study:
- To identify and characterize novel antimitotic agents.
- To investigate the mechanism of action of a new piperazine derivative, CB694.
- To evaluate the efficacy of CB694 in preclinical cancer models.
Main Methods:
- Mechanism-based screening for antimitotic agents.
- Cell proliferation assays (IC50 determination) across various cancer cell lines.
- Mitotic structure analysis in HeLa cells.
- Tubulin assembly inhibition assays.
- In vivo antitumor efficacy studies in murine models.
Main Results:
- CB694, a novel piperazine derivative, identified as a potent microtubule depolymerizing agent.
- CB694 inhibited proliferation of diverse cancer cell lines (average IC50 85 nM), including multidrug-resistant lines.
- Observed G2/M arrest, abnormal mitotic spindle formation (lagging chromosomes, multipolar spindles), and tubulin assembly inhibition (IC50 2.3 microM).
- CB694 binds to the colchicine site on tubulin.
- Demonstrated antitumor activity and good tolerability in a murine solid tumor model.
Conclusions:
- CB694 is a novel antimitotic agent with a mechanism of action involving microtubule depolymerization and disruption of mitosis.
- Its efficacy against multidrug-resistant cells and in vivo antitumor activity suggest therapeutic potential.
- CB694 represents a promising lead compound for the development of new cancer therapies.